Kotecki N[Author] - Search Results

Year	Number of Results
1964	1
1977	5
1978	1
1979	2
1981	1
1983	2
2010	1
2011	1
2012	1
2013	2
2014	1
2015	4
2016	3
2017	2
2018	4
2019	7
2020	2
2021	2

1

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, de Azambuja E. Brandão M, et al. Among authors: kotecki n. Expert Rev Anticancer Ther. 2018 Jul;18(7):629-649. doi: 10.1080/14737140.2018.1477596. Epub 2018 May 24. Expert Rev Anticancer Ther. 2018. PMID: 29781317 Review.

2

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Siu LL, et al. Among authors: kotecki n. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. JAMA Oncol. 2019. PMID: 30383184 Free PMC article. Clinical Trial.

3

Targeting molecular subtypes in solid cancers: successes and failures.

Assi R, Kotecki N, Awada A. Assi R, et al. Among authors: kotecki n. Curr Opin Oncol. 2020 Sep;32(5):488-493. doi: 10.1097/CCO.0000000000000670. Curr Opin Oncol. 2020. PMID: 32796233 Review.

4

Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives.

Kotecki N, Awada A. Kotecki N, et al. Curr Opin Oncol. 2019 Sep;31(5):439-444. doi: 10.1097/CCO.0000000000000565. Curr Opin Oncol. 2019. PMID: 31335832 Review.

5

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A. Castelo-Branco L, et al. Among authors: kotecki n. Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563. Curr Opin Oncol. 2019. PMID: 31335831 Review.

6

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Kotecki N, Gombos A, Awada A. Kotecki N, et al. Expert Rev Anticancer Ther. 2019 Jun;19(6):447-454. doi: 10.1080/14737140.2019.1613892. Epub 2019 May 13. Expert Rev Anticancer Ther. 2019. PMID: 31082272 Review.

7

Tackling the challenges of brain metastases in solid tumors.

Kotecki N, Awada A. Kotecki N, et al. Curr Opin Oncol. 2018 Sep;30(5):330-331. doi: 10.1097/CCO.0000000000000472. Curr Opin Oncol. 2018. PMID: 30096097 No abstract available.

8

How to emerge from the conservatism in clinical research methodology?

Kotecki N, Penel N, Awada A. Kotecki N, et al. Curr Opin Oncol. 2017 Sep;29(5):400-404. doi: 10.1097/CCO.0000000000000399. Curr Opin Oncol. 2017. PMID: 28704211 Review.

9

[Factitious diseases in oncology].

Reich M, Clermont A, Amela É, Kotecki N. Reich M, et al. Among authors: kotecki n. Bull Cancer. 2015 Dec;102(12):1036-45. doi: 10.1016/j.bulcan.2015.09.006. Epub 2015 Nov 18. Bull Cancer. 2015. PMID: 26597474 Review. French.

10

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.

Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, De Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, Azambuja E. Franzoi MA, et al. Among authors: kotecki n. J Natl Cancer Inst. 2021 Apr 6;113(4):462-470. doi: 10.1093/jnci/djaa116. J Natl Cancer Inst. 2021. PMID: 32750143

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results